Opthea to Present at the FLORetina 2023 Congress
01 déc. 2023 05h30 HE
|
Opthea Limited
MELBOURNE, Australia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea to Present at the Jefferies 2023 London Healthcare Conference
09 nov. 2023 05h30 HE
|
Opthea Limited
MELBOURNE, Australia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference
30 oct. 2023 05h30 HE
|
Opthea Limited
MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO
27 oct. 2023 05h30 HE
|
Opthea Limited
Dr. Megan Baldwin transitions to Founder, Chief Innovation Officer and remains on the Board of Directors Experienced pharmaceutical executives Dr. Frederic Guerard appointed as CEO and Peter...
Opthea to Participate at the 2023 Euretina Congress
02 oct. 2023 05h30 HE
|
Opthea Limited
MELBOURNE, Australia, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference
07 sept. 2023 05h30 HE
|
Opthea Limited
MELBOURNE, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million¹)
28 août 2023 05h30 HE
|
Opthea Limited
OPT has successfully completed the placement and institutional entitlement offer components of its previously announced capital raisingAs a result of strong demand from both existing and new domestic...
Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302
26 juil. 2023 06h00 HE
|
Opthea Limited
MELBOURNE, Australia, July 26, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea to Present at the 2023 Ophthalmology Innovation Summit
24 juil. 2023 06h00 HE
|
Opthea Limited
MELBOURNE, Australia, July 24, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea to Feature at the American Society of Retina Specialists 2023 Annual Meeting
13 juil. 2023 06h00 HE
|
Opthea Limited
Podium presentation on the pharmacokinetics and safety of OPT-302 in retinal vascular diseasesParticipation in “Live From ASRS” virtual KOL discussion on market trends and new treatments in wet AMD...